We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| SpringWorks Therapeutics Inc | NASDAQ:SWTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.52 | 1.22% | 42.98 | 41.34 | 46.42 | 43.01 | 41.86 | 42.20 | 553,169 | 23:11:53 |
From May 2023 to May 2024
By Colin Kellaher
SpringWorks Therapeutics on Monday said the U.S. Food and Drug Administration has extended its review of the company's application seeking approval of nirogacestat for adults with desmoid tumors by three months.
SpringWorks said the FDA needs more time to review additional analyses of previously submitted data that the Stamford, Conn., clinical-stage biopharmaceutical company provided at the agency's request.
SpringWorks said the FDA has extended its target action date on the application to Nov. 27 from Aug. 27, adding that the agency hasn't requested any additional data or studies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2023 07:33 ET (11:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year SpringWorks Therapeutics Chart |
1 Month SpringWorks Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
